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Abstract
Background: New glaucoma diagnostic technologies are penetrating 
clinical care and are changing rapidly. Having a systematic review 
of these technologies will help clinicians and decision makers and 
help identify gaps that need to be addressed. This systematic review 
studied five glaucoma technologies compared to the gold standard of 
white on white perimetry for glaucoma detection.
Methods: OVID® interface: MEDLINE® (In-Process & Other Non-
Indexed Citations), EMBASE®, BIOSIS Previews®, CINAHL®, 
PubMed, and the Cochrane Library were searched. A gray literature 
search was also performed. A technical expert panel, information spe-
cialists, systematic review method experts and biostatisticians were 
used. A PRISMA flow diagram was created and a random effect meta-
analysis was performed.
Results: A total of 2,474 articles were screened. The greatest accura-
cy was found with frequency doubling technology (FDT) (diagnostic 
odds ratio (DOR): 57.7) followed by blue on yellow perimetry (DOR: 
46.7), optical coherence tomography (OCT) (DOR: 41.8), GDx 
(DOR: 32.4) and Heidelberg retina tomography (HRT) (DOR: 17.8). 
Of greatest concern is that tests for heterogeneity were all above 50%, 
indicating that cutoffs used in these newer technologies were all very 
varied and not uniform across studies.
Conclusions: Glaucoma content experts need to establish uniform 
cutoffs for these newer technologies, so that studies that compare 
these technologies can be interpreted more uniformly. Nevertheless, 
synthesized data at this time demonstrate that amongst the newest 
technologies, OCT has the highest glaucoma diagnostic accuracy fol-
lowed by GDx and then HRT.
Keywords: Glaucoma; Diagnostic techniques; Diagnostic accura-
cies; Systematic review; Meta-analysis
Introduction
With the aging Western populations, special attention needs to 
be directed to the research of age-related eye diseases. Glau-
coma is one of the leading causes of visual loss and blindness 
in the working age population in industrialized countries [1-
4]. In most Western nations, aside from age-related macular 
degeneration, glaucoma is the next most common cause of 
permanent vision loss in persons aged 40 years or older [5]. 
Along with diabetic retinopathy, glaucoma is also one of the 
most important diseases affecting the visual system in the 
working age population [3-5]. Finally, the extensive and in-
tensive work needed to make the diagnosis, the multiple man-
agement changes needed over the course of the disease, and 
the life-long follow-up required arguably make this condition 
the most important ocular disease from the health services 
standpoint.
Previous research has shown that early diagnosis and 
treatment for glaucoma reduces the rate of disease progres-
sion and improves the patients’ quality of life [6]. The cur-
rent “gold standards” for glaucoma diagnosis are optic disc 
assessment (monitors structural change) and standard achro-
matic white on white perimetry (monitors functional change) 
[7].
Several diagnostic technologies were recently developed 
for early glaucoma diagnosis and progression.
1) Heidelberg retina tomography (HRT) [8, 9] uses a 675 
nm frequency diode laser beam to produce a scanning laser 
ophthalmoscopic image. The laser light scans the retina in 24 
ms sequential scans, starting above the retinal surface, and 
then capturing parallel images at increasing depths. The stacks 
of images are combined to create a three-dimensional (3D) 
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topographic image of the retina.
2) Optical coherence tomography (OCT) [10-13] pro-
vides high-resolution cross-sectional imaging of ocular tis-
sues (retina, optic nerve, and anterior segment). The tech-
nique is analogous to ultrasound except that light instead of 
sound waves is used. OCTs operate on the principle of indi-
rect interferometry. Low coherence infrared light is directed 
to the tissue being imaged. An interferometer (beam splitter) 
is used to split the light. Half of the light goes to the target 
tissue and the other half goes into a reference arm (typically 
a mirror).
3) Scanning laser polarimetry (GDx variable corneal com-
pensator (VCC) access) [14-16] uses a near infrared laser beam 
to measure the thickness of the retinal nerve fiber layer. This 
technology is based on the optical attribute of birefringence 
(parallel arrangement of the microtubules within the axons). 
The nerve fiber layer birefringence causes the polarized laser 
beam to split into two parallel rays and creates a phase shift 
between them; one is more distorted than the other.
4) Frequency doubling technology (FDT) is a form of pe-
rimetry developed to detect ganglion cell death in early glau-
comatous damage. Studies [17, 18] hypothesize that a subset of 
M cells, called “non-linear” M cells, are usually the first to die 
during glaucomatous damage. This subset of cells is thought 
to be responsible for the transmission of signals related to the 
frequency doubling illusion.
5) Blue on yellow automated perimetry [19-22] isolates 
and measures blue-yellow ganglion cell function with a 440 
nm stimulus. Blue-yellow ganglion cells are believed to be one 
of the first cell types damaged in glaucoma and thus seem to be 
important in early glaucoma detection.
The diagnostic instruments listed above have been report-
ed to detect glaucomatous damage. There is some evidence 
that earlier damage can be detected with HRT than with clini-
cal examination or fundus photography [23, 24]. However, 
there has not been a comprehensive report on its accuracy 
compared to that of the reference standard. The goal of this 
systematic review is to summarize the diagnostic accuracy of 
recently developed glaucoma diagnostic technologies com-
pared to the currently available gold standard, white on white 
perimetry.
Materials and Methods
Overview of evidence report
The research synthesis for glaucoma diagnostic accuracies was 
based on a rigorous systematic review of all published reports. 
Together with content experts, methodologists, information 
specialists, and statisticians, the evidence review staff identi-
fied specific issues and approaches necessary for limiting bias 
in the review.
A technical expert panel (TEP) identified the keywords to 
be used in the literature search. The methodological quality 
and generalizability (internal and external validity) of the in-
cluded studies were critically appraised and summarized, as 
was individual study results.
Sources of data
The search strategy for this project was comprehensive and 
was tailored to achieve the highest possible recall of relevant 
studies. An electronic search strategy was developed by an 
information specialist in consultation with four clinical con-
tent experts in glaucoma diagnostics. Searches were restricted 
from 1993 onward to exclude obsolete diagnostic options. 
The search end date was February 2015. Any study provid-
ing information on the sensitivity, specificity, likelihood ratio, 
receiver-operating characteristic (ROC) curves, or diagnostic 
odds ratios (DORs) of a glaucoma diagnostic test was includ-
ed. Specific search terms tailored for diagnostic testing have 
been empirically studied and were used [25, 26]. Published 
and unpublished human studies of any design were considered. 
The reference standard used was standard achromatic white on 
white perimetry.
The following bibliographic databases were searched 
through the OVID® interface: MEDLINE® (In-Process & Oth-
er Non-Indexed Citations), EMBASE®, BIOSIS Previews®, 
CINAHL®, PubMed, and the Cochrane Library. Controlled 
vocabulary and keywords used in the search included terms 
for glaucoma diagnostic testing including the specific evalua-
tive tests and the gold standard test already mentioned in these 
methods. Methodological filters were applied to limit retrieval 
to relevant clinical methodologies applicable to diagnostic 
testing.
The gray literature was searched including websites of 
health technology assessment and related agencies, profes-
sional associations, and other specialized databases. GoogleTM 
and other Internet search engines were used to search for ad-
ditional web-based materials and information. These search-
es were supplemented by hand searching the bibliographies 
and abstracts of key papers and conference proceedings, and 
through contacts with appropriate experts and agencies. These 
include the Association for Research in Vision and Ophthal-
mology, the American Academy of Ophthalmology, the Euro-
pean Ophthalmology Society and The Canadian Ophthalmol-
ogy Association.
Inclusion criteria
Any study evaluating testing outcomes for open angle glau-
coma diagnosis was considered for inclusion in our review 
to maximize interpretability and generalizability. A stand-
ardized and accepted approach for gold standard assessment 
in study populations (white on white automated perimetry) 
was required for inclusion. We originally were to include 
optic disc photographs as a parallel gold standard but there 
were so few studies that used this gold standard that it was 
impractical to use this as a reference standard. Only stud-
ies with a minimum of 20 adult patients were included. Any 
geographic study type (single vs. multi-center) was included 
as was any sampling strategy. Patients from all ethnic back-
ground and studies conducted in any country were included. 
Patients from all study bases were included (population or 
clinic based samples). All patients included were 18 years of 
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age or older.
Study selection
Specific screening questions were drafted for all levels of rele-
vance assessment, and following an appropriate calibration exer-
cise, screening was performed by two independent reviewers. All 
records were uploaded to a software program (EPPI reviewer) to 
help manage the review. All records retrieved through searches 
underwent broad screening initially (level I) using titles, keywords 
and abstracts, if available. All records tagged by one or more re-
viewers as potentially relevant or “can’t tell” (including reviews, 
statements and original studies) were screened for inclusion at the 
next level (full-text relevance, level II) using stricter a priori eli-
gibility criteria. Reference lists of reviews that were thought to be 
relevant were also checked for potentially relevant publications.
At levels where consensus was required, and when disa-
greements occurred, consensus was achieved through discus-
sion. When agreement could not be achieved, third party adju-
dication was used to break the impasse. Reasons for exclusion 
of studies were documented and reported in the review. The 
study followed the PRISMA statement methodology and a 
PRISMA flow diagram was used to report the flow of records 
throughout the review [27].
Data extraction
An electronic data abstraction form was developed a priori 
and tailored specifically for this review. Data collected in-
cluded study identification data (country, language, and cita-
tion), research methods data (study design, sites, and inclusion/
exclusion criteria), population baseline variables (sample size 
Figure 1. The PRISMA study process summarized in flowchart format. 
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complete and enrolled, mean age, gender, and race), clinical 
variables (visual acuity, IOP, C/D ratio, and central cornea thick-
ness), white on white VF variables (mean defect, and corrected 
pattern standard deviation) and index technology variables 
(cutoffs and methods used). Following a calibration exercise on 
a random sample of studies, one data abstractor independently 
abstracted data, and a second reviewer then independently veri-
fied the data. The data form was designed to capture all relevant 
data. For example, study population characteristics as well as 
characteristics of the study itself that might identify potential 
sources of bias were included. In studies where multiple sen-
sitivities and specificities were provided, we always chose the 
value for the highest sensitivity reported and then chose the 
corresponding specificity with it. If data were reported as nor-
mal vs. “mild”, “moderate”, and “severe” glaucoma, we always 
chose to report “mild” as this gives us the most important diag-
nostic information (e.g. “advanced” glaucoma is much easier to 
diagnose and hence the test is less useful).
Study quality assessment
The QUADAS [28, 29] 14-item assessment tool was used to 
assess bias (nine items), variability (affecting generalizability) 
(two items) and to some extent, the quality of reporting (three 
items). Each item is to be scored “yes,” “no,” or “unclear.”
Methods for synthesizing findings - data analysis
Random-effects meta-analysis was performed for each diag-
nostic instrument where possible and stratified by the type of 
summary statistics available from eligible studies. For most 
aspects of meta-analysis, it is preferred that the diagnostic 
threshold be the same across different studies before the pa-
rameters are pooled for analysis. However, ROC curves can be 
pooled for different diagnostic thresholds if variance is provid-
ed. The parameters of interest included sensitivities, specifici-
ties, likelihood ratios, ROC curves, and DORs. The DOR is a 
parameter that combines sensitivity and specificity and ranges 
from 0 to infinity with higher values indicating greater test per-
formance. Because DORs combine the results of both sensitiv-
ity and specificity, we used this as our primary outcome.
Summary of synthesized deliverables
We organized the review to answer both primary and second-
Table 1.  Overall Assessment of Study Quality, Accuracy and Generalizability (QUADAS)
Items % assessed as yes % assessed as no % assessed as unclear
1. Was the spectrum of patients representative of the patients who will  
receive the test in practice?
44 15 41
2. Were selection criteria clearly described? 82 1 17
3. Is the reference standard likely to correctly classify the target  
condition?
93 4 3
4. Is the time period between reference standard and index test short 
enough to be reasonably sure that the target condition did not change  
between the two tests?
93 0 7
5. Did the whole sample or a random selection of the sample, receive  
verification using a reference standard of diagnosis?
73 3 24
6. Did patients receive the same reference standard 
regardless of the index test result?
99 0 1
7. Was the reference standard independent of the index test (i.e. the  
index test did 1t form part of the reference standard)?
99 0 1
8. Was the execution of the index test described in sufficient detail to  
permit replication of the test?
97 1 2
9. Was the execution of the reference standard described in sufficient  
detail to permit its replication?
95 2 3
10. Were the index test results interpreted without knowledge of the  
results of the reference standard?
82 3 15
11. Were the reference standard results interpreted without knowledge of  
the results of the index test?
22 6 72
12. Were the same clinical data available when test results were 
interpreted as would be available when the test is used in practice?
26 2 72
13. Were un-interpretable/ intermediate test results reported? 69 9 22
14. Were withdrawals from the study explained? 42 21 37
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ary research questions.
The primary research question addressed the diagnostic 
accuracies of five index technologies for glaucoma screening: 
1) confocal scanning laser ophthalmoscopy (divided into HRT 
I-II and HRT III); 2) OCT; 3) scanning laser polarimetry; 4) 
blue on yellow automated perimetry; and 5) FDT.
A variety of models are available for each index technol-
ogy. Secondary research questions that were addressed were 
how the models of each index technology compare against 
gold standard for glaucoma diagnosis. The specific second-
ary technologies studied were as the following: 1) FDT (no 
subdivisions). 2) OCT (time domain, spectral domain, and 
OCT spectralis by Heidelberg). 3) Confocal scanning laser 
ophthalmoscopy (HRT I and HRT II; HRT III). 4) Blue on yel-
low automated perimetry (no subdivisions). Although Swed-
ish interactive threshold algorithm and full threshold are two 
available options, most studies included in this review did not 
indicate which of the two programs were utilized. 5) Scanning 
laser polarimetry (GDx VCC; GDx fixed corneal compensator 
(FCC)).
Results
The study process was summarized in the PRISMA flowchart 
(Fig. 1).
Study quality
Table 1 summarizes the study quality and generalizability 
based on the QUADAS questions. Most of the accuracy/qual-
ity indicators rated the studies as very good to excellent. The 
generalizability indicators were moderate to good.
Study characteristics
Overall 357 studies were included in the analysis. There were 
53.8% female and 46.2% male (reported in 256 studies). The 
mean age of the participants was 58.4 years, ranging from 41.0 
to 69.7 years. Overall 42.9% of the participants were Cauca-
sian. All studies reviewed were studies of glaucoma diagnosis. 
No studies of progression were used.
Diagnostic accuracy of technology
Table 2 summarizes the sensitivity, specificity and DOR for 
each of our primary and secondary outcomes. As can be seen 
from the results, amongst the primary outcomes, the high-
est DOR is from FDT followed by blue on yellow perimetry 
(but with the fewest studies and widest confidence intervals). 
Hence, the “older” new technologies had the highest DORs. 
Amongst the “newer” new technologies, OCT had the high-
est DOR followed by scanning laser (GDx), and HRT had the 
lowest accuracy.
When we stratified our technologies into our secondary 
outcomes, the results are similar but there are a few additional 
important points. First, the spectral domain OCT performed 
much better than the time domain OCT. Secondly, the GDx 
VCC performed much better than the GDx FCC. Finally, the 
HRT III has not shown an increase in diagnostic performance 
over HRT I and II. We also tried to stratify the data by study 
size, separating clinical based studies from larger population-
based epidemiology studies. Unfortunately, only three popula-
Table 2.  Accuracy of Diagnostic Technologies (Listed By Number of Studies Reviewed)
# Studies Pooled results
Sensitivity Specificity Sensitivity Specificity Diagnostic odds ratio
Primary analysis
  HRT 132 132 78.8 (76.6 - 80.8) 82.8 (80.6 - 84.7) 17.8 (15.2 - 20.8)
  GDx (FCC and VCC) 103 103 84.5 (81.7 - 87.0) 85.6 (82.9 - 87.9) 32.4 (25.6 - 40.9)
  OCT (all types) 84 84 83.2 (80.7 - 85.4) 89.4 (87.5 - 91.0) 41.8 (33.5 - 52.0)
  FDT 57 57 84.7 (79.1 - 89.0) 91.2 (88.2 - 93.5) 57.7 (35.8 - 92.9)
  Blue on yellow 5 6 87.2 (67.2 - 95.8) 83.2 (68.4 - 91.9) 46.7 (7.58 - 288.2)
Secondary analysis
  HRT I and II 102 102 77.8 (75.3 - 80.0) 84.5 (82.2 - 86.6) 19.1 (15.7 - 23.1)
  HRT III 30 30 81.9 (77.3 - 85.7) 76.3 (71.7 - 80.4) 14.6 (11.4 - 18.6)
  GDx-VCC 98 98 84.9 (82.1 - 87.3) 85.7 (83.0 - 88.0) 33.7 (26.4 - 42.9)
  GDx-FCC 5 5 76.6 (60.0 - 87.7) 84.2 (61.5 - 94.7) 17.5 (8.9 - 34.1)
  OCT time domain stratus 67 67 83.2 (80.4 - 85.6) 88.7 (86.5 - 90.6) 38.7 (30.2 - 49.7)
  OCT spectral domain cirrus 17 17 83.3 (77.2 - 88.0) 91.6 (87.8 - 94.2) 54.1 (34.9 - 83.9)
  OCT-spectralis 1 1 Only one study - no pooled results
  FDT 57 57 84.7 (79.1 - 89.0) 91.2 (88.2 - 93.5) 57.7 (35.8 - 92.9)
  Blue on yellow 5 6 87.2 (67.2 - 95.8) 83.2 (68.4 - 91.9) 46.7 (7.58 - 288.2)
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tion-based studies were found and all studied FDT only com-
pared to gold standard. Hence, this stratified meta-analysis was 
not possible.
Sub-analyses
Table 3 demonstrates all of the sub-analyses performed. In col-
umn 2 of the table, we recalculated the DORs after removing 
outlier studies (based on the Begg’s test). As can be seen, there 
was little difference in the results when these outlier studies 
were removed. Next we looked at DORs from peer reviewed 
vs Industry funded studies. In this analysis we postulated that 
there may be higher DORs from industry funded studies over 
peer reviewed studies as there may be a bias to obtain good 
results for retail purposes. However, the results did not show 
this. While some technologies had a small increase in DORs 
amongst industry funded studies, others showed higher DORs 
from peer reviewed funding. Overall there was no significant 
pattern of increased DORs from industry vs. peer reviewed 
funded studies. We also looked at whether age had an influence 
on the diagnostic accuracy of the technologies. We found that 
when we divided studies into those where mean age was over 
55 vs. under 55, the under 55 group did better in almost every 
analysis. When we divided the studies based on predominance 
of Caucasians as the majority race, we found that almost all 
technologies performed better amongst Caucasians vs. non-
Caucasians. Finally, most of the technologies had higher ac-
Table 3.  Sub-Analysis of Accuracy of Diagnostic Technology (Based on Outlier Removal, Funding Source, Age, Race and Gender)















HRT 17.82 18.18 16.94 18.56 17.56 19.99 19 13.99 17.64 18.62 0.839
GDx 32.38 29.53 35.61 30.12 31.67 41.41 33.2 24.65 33.49 31.23 0.881
OCT 41.76 43.36 39.29 43.62 41.26 47.11 43.2 38.92 49.14 25.94 0.901
FDT 57.7 60.96 57.29 58.03 56.01 61.18 57.53 67.71 57.53 45.44 0.893
BY 46.7 NA NA NA NA NA NA NA NA NA 0.888
HRT I-II 19.05 19.87 16.41 22.96 19.11 17.81 18.45 16.35 18.45 22.25 0.843
HRT III 14.56 15.17 24.5 13.1 13.82 NA 16.89 10.72 15.31 13.07 0.829
GDx VCC 33.65 31.27 35.61 32.06 32.97 41.41 34.54 24.5 35.09 31.61 0.882
GDx FCC 17.46 17.46 NA 17.46 17.46 NA 15.03 NA 15.03 NA 0.859
OCT-T 38.73 38 34.15 42.92 38.66 50.13 41.28 31.63 45.34 23.91 0.898
OCT-C 54.12 54.12 95.27 46 54.2 56.79 62.28 47.8 66.99 31.98 0.907
OCT-S NA NA NA NA NA NA NA NA NA NA 0.88
Table 4.  Heterogeneity of Diagnostic Technology
Technology Sensitivity I2 Specificity I2 Diagnostic odds ratio I2
Primary outcome
  HRT 68.7 86.3 71.4
  GDx 86.2 85.3 72.5
  OCT 75.3 73.7 69.5
  FDT 97.5 94.7 94.3
  Blue on yellow 79.8 79.1 84.4
Secondary outcomes
  HRT I and II 78.7 87.3 81.4
  HRT III 60.9 85.3 62.1
  Scanning laser VCC 86.6 85.2 74.5
  Scanning laser FCC 85.5 83.3 84.0
  Time domain OCT 76.7 75.6 70.5
  Spectral domain OCT 73.0 63.7 65.9
  FDT 97.5 94.7 94.3
  Blue on yellow 79.8 79.1 84.4
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curacy amongst women over men.
Heterogeneity
Table 4 summarizes I2 for each technology stratified by sensi-
tivity, specificity and DOR. This statistic is a statistic of homo-
geneity. In other words, it tells us how similar the studies are 
that are compared. Studies that are similar tend to pool results 
with the same cutoff and their technologies have a significant 
amount of agreement between users. Their I2 values are close 
to zero or are at least less than 50. An I2 above 50 and even 
close to 100 as is true for these technologies demonstrates a 
large amount of heterogeneity.
The reason for such a large amount of heterogeneity was 
explored and can be summarized by simply tabulating the to-
tal number of different methods and cutoffs used to assess the 
technology in question. As an example, for OCT it is possible 
to assess any clock hour, quadrant or average nerve fiber layer 
thickness to assess the detection of glaucoma. Furthermore, 
what cutoff is used to accept the diagnosis of glaucoma can 
be different from study to study even for the same assessment 
(e.g. average nerve fiber layer thickness). The total number of 
methods and cutoffs used in our systematic review are sum-
marized in Table 5.
Discussion
The QUADAS tool reveals that the overall quality within indi-
vidual studies was very good (almost 75% of individual items 
were positive). However, one of the most important conclu-
sions from this study is that the heterogeneity of these new 
glaucoma tests between studies is very high. This is disap-
pointing given that there were 2,474 articles screened which 
makes the review very comprehensive and generalizable. 
When methods of outcome analysis, as well as cutoffs are this 
varied, it is very difficult to be certain about the accuracy and 
effectiveness of a test. It is our conclusion that the content ex-
perts of this field need to determine cutoffs and methods that 
can be agreed upon to make these tests more uniform. At that 
point, the most accurate comparisons between technologies 
will be made. A pervasive challenge with all of these diagnos-
tic tools is the heavy marketing influence that can add further 
inconsistencies and heterogeneity in their utilization.
Nevertheless, the synthesis of existing data, though varied 
and heterogeneous, does give us some interesting information 
that is useful. First, of the five main technologies tested, the 
highest DOR, mainly based on specificity occurred with FDT. 
The next highest DOR belonged to blue on yellow perimetry 
based on a high sensitivity. Both of these “new” diagnostic 
tests have been with us for over a decade but are not in wide-
spread use. Of the newer technologies, OCT had the highest 
accuracy (especially spectral domain OCT) followed by GDx. 
GDx VCC had a higher accuracy than GDx FCC. Finally, HRT 
was the least accurate and accuracy parameters for HRT I and 
II were not very different than HRT III. These are interesting 
results given that the HRT was heavily marketed for utilization 
in the management of glaucoma being the first technology to 
have a reasonable normative database as well as progression 
monitoring software.
When we stratified the main technologies into several 
secondary technologies, other interesting information was re-
vealed. The stratus OCT was much more accurate, especially 
more specific than the time domain OCT. This is not surprising 
as each new generation of OCT has offered substantially more 
resolution than its predecessor. Compared to HRT, upgrades in 
the OCT technology have been more frequent but progression 
assessment has not been possible to date.
The scanning laser (GDx) with a VCC was much more 
sensitive and specific than the GDx with an FCC. Although 
GDx was one of the first to be introduced, it has lagged behind 
the other two in terms of general adoption into clinical practice 
and seems to be less popular today.
Sub-analyses showed that outliers did not influence our 
results. This means that the results found are robust to a few 
studies that may “pull” the means disproportionately. Our re-
sults were not influenced by funding source, industry vs. peer 
reviewed. Our results were more accurate amongst younger 
patients, Caucasians and women.
Synthesis studies of these new technologies are made es-
pecially challenging by the rapid pace of software changes 
for all of the methods. This makes assessing the technologies 
difficult as technology changes can occur even before robust 
evidence syntheses can be completed with evidence-based 
methodology.
In summary, work needs to be done by glaucoma content 
experts to create a more homogenous consensus regarding 
how to utilize the new technologies and to agree on cutoffs. 
At that point, it will be possible to determine if our conclu-
sions regarding the relative accuracy of these newer technolo-
gies remains valid. However, synthesis of results at this point 
in time indicates that amongst the newer glaucoma diagnostic 
technologies, OCT is the most accurate followed by GDx and 
then HRT.
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